You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Riluzole Prodrugs for Melanoma and ALS
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: 102We have discovered a novel Type IIb prodrug of riluzole, trigriluzole (FC-4157, BVH-4157), which has the potential to substantially improve therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action. While riluzole has shown promising efficacy in treating melanoma in patients, trigrilluzole is andgt;20X more potent than riluzo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a urine test for the early detection of liver cancer
SBC: JBS SCIENCE INC Topic: 102Development of a urine test for the early detection of liver cancer The need to develop an effective method for detecting liver cancer is urgent. HCC, a primary liver cancer, is the third leading cause of cancer deaths worldwide and the fastest rising cancer in US. HCC has a 5-year survival rate of less than 15%, if detected early, the survival rate can be as high as 40%. The survival rate drops s ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDProject Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
SBC: Oncoceutics, Inc. Topic: 102Project Summary We propose a two-arm adaptive Phase II clinical trial to evaluate ONC201, a selective antagonist of the G protein-coupled receptor (GPCR) dopamine receptor domain 2 (DRD2), in recurrent glioblastoma (GBM) and diffuse midline glioma associated with very poor prognoses and limited treatment options. DRD2 is overexpressed in high grade gliomas and controls Akt/ERK signaling pathways. ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension
SBC: PhaseBio Pharmaceuticals Inc Topic: NHLBIPulmonary arterial hypertensionPAHis a rarerapidly progressive and fatal disease that is characterized by pulmonary arterial remodelingsevere pulmonary hypertensionand progressive right heart failureThe prognosis of PAH is poor with an approximatemortality withinyear on modern therapyOver the past two decadesa number of medications for the treatment of PAH have been shown to improve patient sympto ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease
SBC: Praeventix, LLC Topic: 300Inflammatory bowel diseaseIBDis a major unresolved medical issue impacting overmillion patients in the United States aloneAs ofthe global IBD therapeutics market had an estimated value of over $billionand it is anticipated that the market will grow to over $billion by the end ofIBD consists of two major disordersCrohn s disease and ulcerative colitisboth of which are typified by severe and chronic ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
TABA: Tools for the site-specific labeling and immobilization of antibodies for immunoassays
SBC: ALPHATHERA Topic: NIBIBSummary: AlphaThera continues to scale commercialization of its site-specific antibody conjugation products and has encountered welcoming signs of consumer interest across the US and the world, with sales in several countries and continued customer inquiries. However, increasing expenses associated with scaling and commercialization have led us to explore additional sources of funds. The TABA fund ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction
SBC: COGNITION THERAPEUTICS, INC. Topic: NIAAbstractProject Summary Cognition Therapeutics IncsCogrxmission is to develop effective therapeutics for Alzheimer s diseaseADOligomers of the brain protein Amyloid betaA Oshave been identified as toxic components that are involved with disease progressionCognition has identified a subset of sigmareceptor binding modulators that displaces A Os from synaptic receptor sites and clears them into the ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a JBS HI-LO Urine DNA Kit
SBC: JBS SCIENCE INC Topic: 172Development of a JBS Hi Lo urine DNA kit There is a critical need for sensitive and cost effective technologies that can obtain high quality and comprehensive genomic data from easy to collect and handle human specimensCurrentlyfresh or frozen whole blood is the most commonly used source to obtain high quality and comprehensive genomic dataHoweverthe use of whole blood requires stringent collectio ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS
SBC: EVRYS BIO LLC Topic: NIAIDDESCRIPTIONprovided by applicantCurrent antivirals for influenza infection target specific viral proteinsDue to marked genetic diversitydifferent strains of influenza demonstrate differential sensitivity to marketed anti influenza drugsAdditionallycurrent drugs remain vulnerable to the rapid development of virus resistanceThe present project proposes to validate a paradigm shifting antiviral mecha ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health